Fintel reports that on November 5, 2024, Stifel upgraded their outlook for Alkermes (NasdaqGS:ALKS) from Hold to Buy. Analyst ...

Stifel has upgraded Alkermes (ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. Read more here.

Stifel analyst Paul Matteis upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. Published first on TheFly ...

Stifel upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. After a deep dive on the orexin space, the firm says ...

The consensus rating for Ultragenyx Pharmaceutical is Outperform, based on 6 analyst ratings. With an average one-year price target of $102.33, there's a potential 100.69% upside.

Check the time stamp on this data. Updated AI-Generated Signals for Alkermes Plc (ALKS) available here: ALKS.

Alkermes (NASDAQ:ALKS – Get Free Report) had its target price dropped by equities researchers at The Goldman Sachs Group from ...

Alkermes (NASDAQ:ALKS – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Piper ...

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.9%. Looking ahead, revenue ...

The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness ...

Alkermes (ALKS) reported $378.14 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 0.7%. EPS of $0.73 for the same period compares to $0.64 a year ago.

Alkermes (ALKS) delivered earnings and revenue surprises of -6.41% and 2.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?